Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FMTX Forma Therapeutics (FMTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Forma Therapeutics Stock (NASDAQ:FMTX) 30 days 90 days 365 days Advanced Chart Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Forma Therapeutics alerts:Sign Up Key Stats Today's Range$20.01▼$20.0150-Day Range$19.91▼$20.0152-Week Range$4.95▼$20.68Volume1 shsAverage Volume847,595 shsMarket Capitalization$957.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Read More… Receive FMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FMTX Stock News HeadlinesForma Therapeutics Holdings, Inc. (FMTX)September 25, 2022 | finance.yahoo.comBiotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & MoreSeptember 7, 2022 | finance.yahoo.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.December 23, 2024 | Insiders Exposed (Ad)SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates GMTX, FMTX, SGFY, ECOMSeptember 7, 2022 | apnews.comThe M&A Class Action Firm Announces the Investigation of Forma Therapeutics Holdings, Inc. - FMTXSeptember 7, 2022 | benzinga.com4 Analysts Have This to Say About Forma Therapeutics HldgsSeptember 2, 2022 | markets.businessinsider.comForma Therapeutics: Rare Disease PlaySeptember 2, 2022 | seekingalpha.comNovo Nordisk To Acquire Forma Therapeutics - Quick FactsSeptember 1, 2022 | markets.businessinsider.comSee More Headlines FMTX Stock Analysis - Frequently Asked Questions How were Forma Therapeutics' earnings last quarter? Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.91) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.05. When did Forma Therapeutics IPO? Forma Therapeutics (FMTX) raised $201 million in an initial public offering on Friday, June 19th 2020. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse served as the underwriters for the IPO. What other stocks do shareholders of Forma Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Forma Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Cheniere Energy (LNG), Netflix (NFLX), Domino's Pizza (DPZ), Marvell Technology (MRVL) and Viper Energy (VNOM). Company Calendar Last Earnings11/12/2021Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FMTX CUSIPN/A CIK1538927 Webwww.formatherapeutics.com Phone617-679-1970FaxN/AEmployees166Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-172,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.68% Return on Assets-35.33% Debt Debt-to-Equity RatioN/A Current Ratio12.74 Quick Ratio12.74 Sales & Book Value Annual Sales$100.56 million Price / Sales9.52 Cash FlowN/A Price / Cash FlowN/A Book Value$10.51 per share Price / Book1.90Miscellaneous Outstanding Shares47,853,000Free Float45,082,000Market Cap$957.54 million OptionableNot Optionable Beta-0.94 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:FMTX) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forma Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
